ABBV vs AMGN
ABBV: A diversified global biopharmaceutical leader with a strong footprint in immunology, neuroscience, and aesthetics, supported by a pipeline expanding into obesity. AMGN: Amgen is a leading biotechnology firm dedicated to developing innovative human therapeutics to address critical unmet needs in areas like oncology, inflammation, and cardiovascular disease.
Side-by-side fundamentals
| Metric | ABBV | AMGN | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $272.42 | $407.44 | |
| Market cap | $481.4B | $220.3B | |
| P/E as of 2026-10-08 | 76.54 | 25.30 | AMGN lower |
| Net margin FY2025, SEC XBRL | +6.9% | +21.0% | AMGN higher |
| Operating margin FY2025, SEC XBRL | +24.6% | +24.7% | AMGN higher |
| ROE FY2025, SEC XBRL | n/a | +89.1% | |
| ROA FY2025, SEC XBRL | +3.2% | +8.5% | AMGN higher |
| Debt / equity as of 2026-09-03 | 49.22 | 4.90 | AMGN lower |
| Revenue growth (YoY) as of 2026-09-03 | +10.4% | +9.1% | ABBV higher |
| Revenue CAGR (3y) SEC XBRL | +1.8% | +11.8% | AMGN higher |
| Dividend yield as of 2026-09-03 | +2.6% | +2.6% | ABBV higher |
| Dividend streak (yrs) SEC XBRL | 9 | 15 | AMGN higher |
| Beta as of 2026-09-03 | 0.27 | 0.42 | |
| 1-year return as of 2026-10-08 close | +17.8% | +38.3% | AMGN higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.